{
    "root": "35ab39e4-b393-4125-a88e-cce82611b6ff",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Fluconazole",
    "value": "20250513",
    "ingredients": [
        {
            "name": "FLUCONAZOLE",
            "code": "8VZV102JFY"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        }
    ],
    "indications": "fluconazole tablets indicated treatment : 1.vaginal candidiasis ( vaginal yeast infections due candida ) . 2.oropharyngeal esophageal candidiasis . open noncomparative relatively small numbers patients , fluconazole tablets also effective treatment candida urinary tract infections , peritonitis , systemic candida infections including candidemia , disseminated candidiasis , pneumonia . 3. cryptococcal meningitis . prescribing fluconazole tablets aids patients cryptococcal meningitis , please section . comparing fluconazole tablets amphotericin b non-hiv infected patients conducted . prophylaxis : fluconazole tablets also indicated decrease incidence candidiasis patients undergoing bone marrow transplantation receive cytotoxic chemotherapy and/or radiation therapy . specimens fungal culture relevant laboratory ( serology , histopathology ) obtained prior therapy isolate identify causative organisms . therapy may instituted results cultures laboratory known ; however , results become available , anti-infective therapy adjusted accordingly .",
    "contraindications": null,
    "warningsAndPrecautions": "fluconazole tablets usp , 200 mg pink mottled , biconvex , capsule shaped uncoated tablets “ c ” debossed one side “ 07 ” debossed side . bottles 1 ndc 68788-8526-0 bottles 2 ndc 68788-8526-8 bottles 10 ndc 68788-8526-1 bottles 20 ndc 68788-8526-2 bottles 30 ndc 68788-8526-3 bottles 60 ndc 68788-8526-6 bottles 90 ndc 68788-8526-9 storage store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . maalox® registered trademark novartis consumer health , inc. xeljanz® registered trademark pfizer , inc.lynparza® registered trademark astrazeneca group companies . distributed : rising pharma holdings , inc.east brunswick , nj 08816 made india code : ts/drugs/19/1993 revised : 06/2024 repackaged : preferred pharmaceuticals inc .",
    "adverseReactions": "fluconazole tablets contraindicated patients shown hypersensitivity fluconazole excipients . information regarding cross-hypersensitivity fluconazole azole antifungal agents . caution used prescribing fluconazole tablets patients hypersensitivity azoles . coadministration drugs known prolong qt interval metabolized via enzyme cyp3a4 erythromycin , pimozide , quinidine contraindicated patients receiving fluconazole . ( pharmacology : interaction . )",
    "indications_original": "Fluconazole tablets are indicated for the treatment of:\n                  \n                     \n                        1.Vaginal candidiasis (vaginal yeast infections due to Candida).\n                     \n                        2.Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia.\n                     \n                        3.\n                        Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see \n                           CLINICAL STUDIES\n                         section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. \n                  \n                  Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy.\n                     Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.",
    "warningsAndPrecautions_original": "Fluconazole Tablets USP, 200 mg are pink mottled, biconvex, capsule shaped uncoated tablets with “C” debossed on one side and “07” debossed on other side. \n                                 Bottles of 1                            NDC 68788-8526-0\n                              Bottles of 2                            NDC 68788-8526-8\n                              Bottles of 10                           NDC 68788-8526-1\n                              Bottles of 20                            NDC 68788-8526-2\n                              Bottles of 30                            NDC 68788-8526-3\n                              Bottles of 60                            NDC 68788-8526-6\n                              Bottles of  90                           NDC 68788-8526-9\n                      Storage\n                     \n                     \n                     Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].\n                  Maalox® is a registered trademark of Novartis Consumer Health, Inc. XELJANZ®  is a registered trademark of Pfizer, Inc.LYNPARZA® is a registered trademark of AstraZeneca group of companies.\n                     \n                     Distributed by:\n                     Rising Pharma Holdings, Inc.East Brunswick, NJ 08816\n                     \n                      Made in India\n                     \n                      Code: TS/DRUGS/19/1993\n                      Revised: 06/2024\n                  \n                     Repackaged By: Preferred Pharmaceuticals Inc.",
    "adverseReactions_original": "Fluconazole tablets are contraindicated in patients who have shown hypersensitivity to fluconazole or to any of its excipients. There is no information regarding cross-hypersensitivity between fluconazole and other azole antifungal agents. Caution should be used in prescribing fluconazole tablets to patients with hypersensitivity to other azoles. Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (See \n                        CLINICAL PHARMACOLOGY: Drug Interaction Studies and \n                        PRECAUTIONS\n                     .)"
}